​
​

Aptevo Therapeutics Ownership 2024 | Who Owns Aptevo Therapeutics Now?

OverviewRevenueFinancialsChart

Institutional Ownership

15.37%

Insider Ownership

0.06%

Retail Ownership

84.57%

Institutional Holders

30.00

Aptevo Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
JPMORGAN CHASE & CO----1,897-100.00%-Mar 31, 2024
FIFTH THIRD BANCORP----291-100.00%-Mar 31, 2024
FRANKLIN RESOURCES INC----10,997-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----6-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----1,617-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----14,121-100.00%-Mar 31, 2024
STATE STREET CORP----10,941-100.00%-Mar 31, 2024
VANGUARD GROUP INC----91,725-100.00%-Mar 31, 2024
PNC FINANCIAL SERVICES GROUP, INC.----142-100.00%-Mar 31, 2024
CITIGROUP INC----10-100.00%-Mar 31, 2024
MORGAN STANLEY----11,370-100.00%-Mar 31, 2024
CANTOR FITZGERALD, L. P.----58,532-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----516,789-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----43,201-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----104,608-100.00%-Mar 31, 2024
BLACKROCK INC.----46,635-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----262,124-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----11,248-100.00%-Mar 31, 2024
ALYESKA INVESTMENT GROUP, L.P.----45,980-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----13,660-100.00%-Mar 31, 2024

Aptevo Therapeutics's largest institutional shareholder is JPMORGAN CHASE & CO, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
JPMORGAN CHASE & CO----1,897-100.00%-Mar 31, 2024
FIFTH THIRD BANCORP----291-100.00%-Mar 31, 2024
FRANKLIN RESOURCES INC----10,997-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----6-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----1,617-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----14,121-100.00%-Mar 31, 2024
STATE STREET CORP----10,941-100.00%-Mar 31, 2024
VANGUARD GROUP INC----91,725-100.00%-Mar 31, 2024
PNC FINANCIAL SERVICES GROUP, INC.----142-100.00%-Mar 31, 2024
CITIGROUP INC----10-100.00%-Mar 31, 2024
MORGAN STANLEY----11,370-100.00%-Mar 31, 2024
CANTOR FITZGERALD, L. P.----58,532-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----516,789-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----43,201-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----104,608-100.00%-Mar 31, 2024
BLACKROCK INC.----46,635-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----262,124-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----11,248-100.00%-Mar 31, 2024
ALYESKA INVESTMENT GROUP, L.P.----45,980-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----13,660-100.00%-Mar 31, 2024

The largest Aptevo Therapeutics shareholder by % of total assets is JPMORGAN CHASE & CO. The company owns 0.00 shares of Aptevo Therapeutics (APVO), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
UBS GROUP AG----5-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----6-100.00%-Mar 31, 2024
CITIGROUP INC----10-100.00%-Mar 31, 2024
ALLWORTH FINANCIAL LP----17-100.00%-Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.----30-100.00%-Mar 31, 2024
TRUVESTMENTS CAPITAL LLC----95-100.00%-Mar 31, 2024
PNC FINANCIAL SERVICES GROUP, INC.----142-100.00%-Mar 31, 2024
FIFTH THIRD BANCORP----291-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----1,617-100.00%-Mar 31, 2024
JPMORGAN CHASE & CO----1,897-100.00%-Mar 31, 2024
DIVERGENT WEALTH ADVISORS----10,000-100.00%-Mar 31, 2024
STATE STREET CORP----10,941-100.00%-Mar 31, 2024
FRANKLIN RESOURCES INC----10,997-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----11,248-100.00%-Mar 31, 2024
MORGAN STANLEY----11,370-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----13,660-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----14,121-100.00%-Mar 31, 2024
BAADER BANK AKTIENGESELLSCHAFT----15,086-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----43,201-100.00%-Mar 31, 2024
ALYESKA INVESTMENT GROUP, L.P.----45,980-100.00%-Mar 31, 2024

As of Mar 31 2024, Aptevo Therapeutics's largest institutional buyer is UBS GROUP AG. The company purchased -5.00 stocks of APVO, valued at -.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RENAISSANCE TECHNOLOGIES LLC----516,789-100.00%-Mar 31, 2024
SABBY MANAGEMENT, LLC----349,471-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----262,124-100.00%-Mar 31, 2024
SCHONFELD STRATEGIC ADVISORS LLC----159,000-100.00%-Mar 31, 2024
SQUAREPOINT OPS LLC----138,697-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----104,608-100.00%-Mar 31, 2024
VANGUARD GROUP INC----91,725-100.00%-Mar 31, 2024
ARMISTICE CAPITAL, LLC----61,130-100.00%-Mar 31, 2024
CANTOR FITZGERALD, L. P.----58,532-100.00%-Mar 31, 2024
BLACKROCK INC.----46,635-100.00%-Mar 31, 2024
ALYESKA INVESTMENT GROUP, L.P.----45,980-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----43,201-100.00%-Mar 31, 2024
BAADER BANK AKTIENGESELLSCHAFT----15,086-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----14,121-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----13,660-100.00%-Mar 31, 2024
MORGAN STANLEY----11,370-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----11,248-100.00%-Mar 31, 2024
FRANKLIN RESOURCES INC----10,997-100.00%-Mar 31, 2024
STATE STREET CORP----10,941-100.00%-Mar 31, 2024
DIVERGENT WEALTH ADVISORS----10,000-100.00%-Mar 31, 2024

As of Mar 31 2024, Aptevo Therapeutics's biggest institutional seller is RENAISSANCE TECHNOLOGIES LLC. The company sold -0.52M shares of APVO, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RENAISSANCE TECHNOLOGIES LLC----516,789-100.00%-Mar 31, 2024
SABBY MANAGEMENT, LLC----349,471-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----262,124-100.00%-Mar 31, 2024
SCHONFELD STRATEGIC ADVISORS LLC----159,000-100.00%-Mar 31, 2024
SQUAREPOINT OPS LLC----138,697-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----104,608-100.00%-Mar 31, 2024
VANGUARD GROUP INC----91,725-100.00%-Mar 31, 2024
ARMISTICE CAPITAL, LLC----61,130-100.00%-Mar 31, 2024
CANTOR FITZGERALD, L. P.----58,532-100.00%-Mar 31, 2024
BLACKROCK INC.----46,635-100.00%-Mar 31, 2024
ALYESKA INVESTMENT GROUP, L.P.----45,980-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----43,201-100.00%-Mar 31, 2024
BAADER BANK AKTIENGESELLSCHAFT----15,086-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----14,121-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----13,660-100.00%-Mar 31, 2024
MORGAN STANLEY----11,370-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----11,248-100.00%-Mar 31, 2024
FRANKLIN RESOURCES INC----10,997-100.00%-Mar 31, 2024
STATE STREET CORP----10,941-100.00%-Mar 31, 2024
DIVERGENT WEALTH ADVISORS----10,000-100.00%-Mar 31, 2024
JPMORGAN CHASE & CO----1,897-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----1,617-100.00%-Mar 31, 2024
FIFTH THIRD BANCORP----291-100.00%-Mar 31, 2024
PNC FINANCIAL SERVICES GROUP, INC.----142-100.00%-Mar 31, 2024
TRUVESTMENTS CAPITAL LLC----95-100.00%-Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.----30-100.00%-Mar 31, 2024
ALLWORTH FINANCIAL LP----17-100.00%-Mar 31, 2024
CITIGROUP INC----10-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----6-100.00%-Mar 31, 2024
UBS GROUP AG----5-100.00%-Mar 31, 2024

Aptevo Therapeutics's largest sold out institutional shareholder by shares sold is RENAISSANCE TECHNOLOGIES LLC, sold -0.52M shares, valued at -, as of undefined.

Aptevo Therapeutics Mutual Fund Holders

Name% Total AssetsTotal SharesChange AmountChange %Date
BRIDGEWAY FUNDS INC0.04%83,802--Mar 28, 2024
T. Rowe Price Index Trust, Inc.0.00%46,200--Feb 29, 2024
VANGUARD INDEX FUNDS0.00%822,763--Mar 31, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%28,766--Mar 31, 2024
FIDELITY CONCORD STREET TRUST0.00%143,113--Feb 29, 2024
VANGUARD INDEX FUNDS0.00%183,450--Mar 31, 2024
FIDELITY CONCORD STREET TRUST0.00%41,777--Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%2,287--Mar 31, 2024
SCHWAB CAPITAL TRUST0.00%1,654--Feb 29, 2024
NORTHERN FUNDS0.00%5,531--Mar 28, 2024
VALIC Co I0.00%10,100--Feb 29, 2024
Dimensional ETF Trust0.00%6,015--Jan 31, 2024
VANGUARD INDEX FUNDS0.00%2,0842,084-Mar 31, 2024
DFA INVESTMENT DIMENSIONS GROUP INC0.00%3,470--Jan 31, 2024
USAA MUTUAL FUNDS TRUST0.00%536--Jan 31, 2024
SUNAMERICA SERIES TRUST0.00%709--Jan 31, 2024
Legg Mason Global Asset Management Trust0.00%13,113--Jan 31, 2024
Legg Mason Global Asset Management Trust0.00%10,288--Jan 31, 2024
EQ ADVISORS TRUST0.00%524--Mar 31, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%400--Mar 31, 2024

Aptevo Therapeutics's largest mutual fund holder by % of total assets is "BRIDGEWAY FUNDS INC", owning 83.80K shares, compromising 0.04% of its total assets.

Aptevo Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

DateHoldingsChange %
31 Dec, 233015.38%
30 Sep, 232613.04%
30 Jun, 2323-4.17%
31 Mar, 2324-7.69%
31 Dec, 222630.00%
30 Sep, 2220-
30 Jun, 222011.11%
31 Mar, 2218-
31 Dec, 2118-18.18%
30 Sep, 2122-15.38%
30 Jun, 2126-21.21%
31 Mar, 2133-2.94%
31 Dec, 2034100.00%
30 Sep, 2017-10.53%
30 Jun, 201918.75%
31 Mar, 2016-

As of 31 Dec 23, 30 institutions are holding Aptevo Therapeutics's shares, representing an increase of 15.38% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Dec, 231,933,445-43.29%
30 Sep, 233,409,316267.07%
30 Jun, 23928,8044.17%
31 Mar, 23891,596-7.44%
31 Dec, 22963,25011.08%
30 Sep, 22867,1499.03%
30 Jun, 22795,337-2.03%
31 Mar, 22811,8506.71%
31 Dec, 21760,799-75.57%
30 Sep, 213,114,3235.20%
30 Jun, 212,960,4400.56%
31 Mar, 212,943,8531.18%
31 Dec, 202,909,605341.29%
30 Sep, 20659,3484.30%
30 Jun, 20632,18430.45%
31 Mar, 20484,601-

Aptevo Therapeutics (APVO) has 1.93M shares outstanding as of 31 Dec 23, down -43.29% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Dec, 2315.37%0.56%
30 Sep, 2352.60%30.06%
30 Jun, 2313.23%8.20%
31 Mar, 2312.70%3.56%
31 Dec, 2218.89%6.51%
30 Sep, 2217.03%6.80%
30 Jun, 2215.83%5.86%
31 Mar, 2216.44%6.24%
31 Dec, 2116.23%0.40%
30 Sep, 2163.66%1.49%
30 Jun, 2165.26%1.47%
31 Mar, 2166.63%1.54%
31 Dec, 2065.85%15.83%
30 Sep, 2020.40%5.33%
30 Jun, 2019.56%8.90%
31 Mar, 2014.82%-

As of 31 Dec 23, Aptevo Therapeutics is held by 15.37% institutional shareholders, representing a 0.56% growth compared to 30 Sep 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Dec, 231233.33%
30 Sep, 23980.00%
30 Jun, 235-28.57%
31 Mar, 237-46.15%
31 Dec, 221344.44%
30 Sep, 229-
30 Jun, 22928.57%
31 Mar, 227-12.50%
31 Dec, 218-20.00%
30 Sep, 2110-28.57%
30 Jun, 2114-6.67%
31 Mar, 2115-44.44%
31 Dec, 2027237.50%
30 Sep, 208-11.11%
30 Jun, 209-43.75%
31 Mar, 2016-

12 institutional shareholders have increased their position in APVO stock as of 31 Dec 23 compared to 9 in the previous quarter (a 33.33% increase).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Dec, 23740.00%
30 Sep, 235150.00%
30 Jun, 232-60.00%
31 Mar, 235-37.50%
31 Dec, 228166.67%
30 Sep, 223-57.14%
30 Jun, 22716.67%
31 Mar, 22650.00%
31 Dec, 21433.33%
30 Sep, 213-25.00%
30 Jun, 214-66.67%
31 Mar, 2112200.00%
31 Dec, 204-20.00%
30 Sep, 205-
30 Jun, 205-
31 Mar, 20--

7 institutional shareholders have reduced their position in APVO stock as of 31 Dec 23 compared to 5 in the previous quarter (a 40.00% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Dec, 233015.38%1,933,445-43.29%15.37%0.56%1233.33%740.00%
30 Sep, 232613.04%3,409,316267.07%52.60%30.06%980.00%5150.00%
30 Jun, 2323-4.17%928,8044.17%13.23%8.20%5-28.57%2-60.00%
31 Mar, 2324-7.69%891,596-7.44%12.70%3.56%7-46.15%5-37.50%
31 Dec, 222630.00%963,25011.08%18.89%6.51%1344.44%8166.67%
30 Sep, 2220-867,1499.03%17.03%6.80%9-3-57.14%
30 Jun, 222011.11%795,337-2.03%15.83%5.86%928.57%716.67%
31 Mar, 2218-811,8506.71%16.44%6.24%7-12.50%650.00%
31 Dec, 2118-18.18%760,799-75.57%16.23%0.40%8-20.00%433.33%
30 Sep, 2122-15.38%3,114,3235.20%63.66%1.49%10-28.57%3-25.00%
30 Jun, 2126-21.21%2,960,4400.56%65.26%1.47%14-6.67%4-66.67%
31 Mar, 2133-2.94%2,943,8531.18%66.63%1.54%15-44.44%12200.00%
31 Dec, 2034100.00%2,909,605341.29%65.85%15.83%27237.50%4-20.00%
30 Sep, 2017-10.53%659,3484.30%20.40%5.33%8-11.11%5-
30 Jun, 201918.75%632,18430.45%19.56%8.90%9-43.75%5-
31 Mar, 2016-484,601-14.82%-16---

Aptevo Therapeutics Insider Shareholders Trades

Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 09, 2024Kwon SoYoungofficer SVP, GC, BD & Corp AffairsM-ExemptSell213---
Aug 09, 2024Lamothe Jeffrey G.officer EVP, COOM-ExemptSell42--41
Aug 09, 2024Lamothe Jeffrey G.officer EVP, COOM-ExemptSell272---
Aug 09, 2024Taylor Daphneofficer SVP, CFOM-ExemptSell158---
Jun 03, 2024Niederhuber Johndirector-M-ExemptSell81---

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 09, 2024Kwon SoYoungofficer SVP, GC, BD & Corp AffairsM-ExemptBuy213-$0.21801
Aug 09, 2024Kwon SoYoungofficer SVP, GC, BD & Corp AffairsM-ExemptSell213---
Aug 09, 2024Lamothe Jeffrey G.officer EVP, COOM-ExemptBuy272-$0.271,166
Aug 09, 2024Lamothe Jeffrey G.officer EVP, COOM-ExemptBuy42-$0.04894
Aug 09, 2024Lamothe Jeffrey G.officer EVP, COOM-ExemptSell42--41
Aug 09, 2024Lamothe Jeffrey G.officer EVP, COOM-ExemptSell272---
Aug 09, 2024Taylor Daphneofficer SVP, CFOM-ExemptBuy158-$0.16576
Aug 09, 2024Taylor Daphneofficer SVP, CFOM-ExemptSell158---
Jul 19, 2024Harsanyi Zsoltdirector-A-AwardBuy925--925
Jul 19, 2024Taylor Daphneofficer SVP, CFOA-AwardBuy8,550--8,550
Jul 19, 2024Grant Grady IIIdirector-A-AwardBuy925--925
Jul 19, 2024Kwon SoYoungofficer SVP, GC, BD & Corp AffairsA-AwardBuy8,550--8,550
Jul 19, 2024Lamothe Jeffrey G.officer EVP, COOA-AwardBuy12,825--12,825
Jul 19, 2024White Marvin Ldirector, officer President and CEOA-AwardBuy22,325--22,325
Jul 19, 2024Niederhuber Johndirector-A-AwardBuy925--925
Jul 19, 2024Kunz Barbara Lopezdirector-A-AwardBuy925--925
Jul 19, 2024Abdun-Nabi Danieldirector-A-AwardBuy925--925
Jun 03, 2024Niederhuber Johndirector-M-ExemptBuy81-$0.08217
Jun 03, 2024Niederhuber Johndirector-M-ExemptBuy7-$0.01136
Jun 03, 2024Niederhuber Johndirector-M-ExemptSell81---

The last insider sell of Aptevo Therapeutics's stock was made by Kwon SoYoung on Aug 09 2024, selling 213 shares at - per share (valued at -).

Aptevo Therapeutics Insider Ownership Trends

All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 2024134325.00%
Q2 2024116183.33%
Q1 20241111100.00%
Q3 202399100.00%
Q2 2023116183.33%
Q1 20231412116.67%
Q3 20229--
Q2 202274175.00%
Q1 20229--
Q4 202131717.65%
Q2 202114--
Q1 20216--
Q4 202016--
Q3 2020264360.47%
Q1 20206--
Q4 20196--
Q3 201911--
Q2 201915--
Q1 20191210120.00%
Q4 20182--

13 total buy trades, and 4 total sell trades (buy/sell ratio of 3.25%) were made by Aptevo Therapeutics's insiders, as of Q3 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 2024---
Q2 2024---
Q1 2024---
Q3 2023---
Q2 2023---
Q1 2023---
Q3 2022---
Q2 2022---
Q1 2022---
Q4 2021-17-
Q2 2021---
Q1 2021---
Q4 202016--
Q3 2020---
Q1 2020---
Q4 2019---
Q3 201911--
Q2 20199--
Q1 2019---
Q4 20182--

As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Aptevo Therapeutics's stocks.

Aptevo Therapeutics Peer Ownership

TickerCompany
HOTHHoth Therapeutics, Inc.
MGTADianthus Therapeutics, Inc.
NTRBNutriband Inc.
ACHLAchilles Therapeutics plc
LRMRLarimar Therapeutics, Inc.
LGVNLongeveron Inc.
IVVDInvivyd, Inc.
REVBRevelation Biosciences, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
KRONKronos Bio, Inc.
PASGPassage Bio, Inc.
VRAXVirax Biolabs Group Limited
RNXTRenovoRx, Inc.
CYCNCyclerion Therapeutics, Inc.
NRBONeuroBo Pharmaceuticals, Inc.
ATXIAvenue Therapeutics, Inc.
ADXNAddex Therapeutics Ltd

APVO Ownership FAQ

Aptevo Therapeutics is owned by institutional shareholders (15.37%), insiders (0.06%), and public (84.57%). The largest institutional shareholder of Aptevo Therapeutics is JPMORGAN CHASE & CO (0% of total shares) and the top mutual fund owner is BRIDGEWAY FUNDS INC (0.04% of total shares).

Aptevo Therapeutics's major institutional shareholders are JPMORGAN CHASE & CO, FIFTH THIRD BANCORP, FRANKLIN RESOURCES INC, BANK OF AMERICA CORP /DE/, and WELLS FARGO & COMPANY/MN. The top five shareholders own together 0% of the company's share outstanding.

As of Dec 2023, there are 30 institutional shareholders of Aptevo Therapeutics.

JPMORGAN CHASE & CO owns 0 shares of Aptevo Therapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Mar 2024).

As of Mar 2024, FIFTH THIRD BANCORP holds 0 shares of Aptevo Therapeutics (APVO), compromising 0% of the company, valued at $0.

FRANKLIN RESOURCES INC is the third largest holder of Aptevo Therapeutics. The company owns 0 of the company's shares outstanding (worth $0).